Brokerages Set ProQR Therapeutics NV (NASDAQ:PRQR) PT at $22.25
ProQR Therapeutics NV (NASDAQ:PRQR) has been assigned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the firm. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $17.17.
A number of equities analysts recently issued reports on PRQR shares. Zacks Investment Research upgraded ProQR Therapeutics NV from a “sell” rating to a “hold” rating in a research note on Saturday, September 17th. Janney Montgomery Scott started coverage on ProQR Therapeutics NV in a research note on Wednesday. They issued a “neutral” rating and a $7.00 target price for the company. Chardan Capital started coverage on ProQR Therapeutics NV in a research note on Monday, June 20th. They issued a “neutral” rating and a $4.50 target price for the company. JMP Securities restated a “buy” rating on shares of ProQR Therapeutics NV in a research note on Tuesday, September 6th. Finally, Leerink Swann restated a “buy” rating on shares of ProQR Therapeutics NV in a research note on Thursday, August 18th.
An institutional investor recently raised its position in ProQR Therapeutics NV stock. Redmile Group LLC raised its stake in shares of ProQR Therapeutics NV (NASDAQ:PRQR) by 5.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 581,638 shares of the biopharmaceutical company’s stock after buying an additional 28,925 shares during the period. Redmile Group LLC owned about 2.49% of ProQR Therapeutics NV worth $2,815,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 39.21% of the company’s stock.
ProQR Therapeutics NV (NASDAQ:PRQR) opened at 6.67 on Thursday. The stock has a 50 day moving average price of $6.01 and a 200-day moving average price of $5.23. ProQR Therapeutics NV has a 1-year low of $3.48 and a 1-year high of $16.23. The company’s market cap is $155.72 million.
ProQR Therapeutics NV (NASDAQ:PRQR) last issued its earnings results on Wednesday, August 17th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.00. On average, equities research analysts forecast that ProQR Therapeutics NV will post ($2.09) EPS for the current year.
About ProQR Therapeutics NV
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).
Receive News & Stock Ratings for ProQR Therapeutics NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics NV and related stocks with our FREE daily email newsletter.